Benzinga · Aug 24, 2026
JP Morgan Maintains Underweight on Agilon Health, Raises Price Target to $85
JP Morgan analyst Lisa Gill maintains Agilon Health (NYSE:AGL) with a Underweight and raises the price target from $31 to $85.
AG
NYSE · AGL
Agilon Health, Inc.
Healthcare · Medical - Care Facilities
$94.18
Down-$1.44 (-1.53%)
Updated Aug 28, 2026, 5:59 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 244.31M
- P/E ratio
- -0.62
- Dividend yield
- 0.00%
- 52-week range
- $0.38 – $133.04
- Volume
- 176.44K
- Avg. volume
- 7.47M
Price performance
AGL price history
1M range · 21 trading sessions · Daily adjusted prices
AGL closed at $94.18 after 21 trading sessions, down 2.66% for the selected period.
- Last close
- $94.18
- Period change
- -2.66%
- Period low
- $86.26
- Period high
- $107.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $95.38 | $96.96 | $93.80 | $94.18 | 176.44K |
| Aug 26, 2026 | $94.67 | $99.195 | $94.67 | $95.74 | 155.79K |
| Aug 25, 2026 | $95.20 | $96.48 | $91.18 | $96.11 | 183.99K |
| Aug 24, 2026 | $96.27 | $97.6422 | $91.78 | $93.79 | 216.02K |
| Aug 21, 2026 | $94.12 | $97.00 | $92.02 | $96.58 | 277.39K |
| Aug 20, 2026 | $90.51 | $100.00 | $90.51 | $92.73 | 190.34K |
| Aug 19, 2026 | $97.38 | $97.98 | $92.485 | $93.64 | 268.76K |
| Aug 18, 2026 | $96.42 | $99.90 | $94.90 | $95.40 | 336.76K |
| Aug 17, 2026 | $96.21 | $97.29 | $92.66 | $96.86 | 192.1K |
| Aug 14, 2026 | $90.29 | $97.65 | $89.3475 | $96.90 | 201.15K |
| Aug 13, 2026 | $88.81 | $91.3641 | $86.24 | $88.90 | 231.55K |
| Aug 12, 2026 | $85.90 | $90.8511 | $85.90 | $86.26 | 366.99K |
| Aug 11, 2026 | $100.32 | $101.80 | $86.23 | $86.39 | 394.33K |
| Aug 10, 2026 | $95.51 | $103.88 | $94.555 | $96.78 | 397.28K |
| Aug 7, 2026 | $89.21 | $100.85 | $89.21 | $95.51 | 540.44K |
| Aug 6, 2026 | $100.59 | $100.59 | $86.29 | $86.83 | 921.58K |
| Aug 5, 2026 | $94.78 | $114.32 | $93.73 | $107.85 | 1.12M |
| Aug 4, 2026 | $95.52 | $95.52 | $86.31 | $94.78 | 433.44K |
| Aug 3, 2026 | $92.92 | $97.56 | $91.62 | $94.11 | 425.95K |
| Jul 31, 2026 | $98.20 | $98.20 | $90.74 | $91.61 | 174.02K |
| Jul 30, 2026 | $95.23 | $97.795 | $92.92 | $96.75 | 170.11K |
Latest AGL news
The latest Smart Investors Daily articles mentioning AGL.
Stock researchCompany · Overview
AGL research
Overview
Company profile and research snapshot.
Company profile
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $1.30
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | JP Morgan | Underweight | — |
| Aug 11, 2026 | Wells Fargo | Overweight | — |
| Aug 11, 2026 | Citigroup | Neutral | — |
| Aug 6, 2026 | Evercore ISI Group | In-Line | — |
| Aug 6, 2026 | Barclays | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 20, 2026
agilon health to Participate in Upcoming Conferences
WESTERVILLE, Ohio, August 20, 2026--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that its management team will participate in a fireside chat at the following conferences:
Yahoo · Aug 19, 2026
Q2 Earnings Highlights: agilon health (NYSE:AGL) Vs The Rest Of The Outpatient & Specialty Care Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at agilon health (NYSE:AGL) and the best and worst performers in the outpatient & specialty care industry.
Yahoo · Aug 14, 2026
5 Insightful Analyst Questions From agilon health’s Q2 Earnings Call
Agilon Health’s second quarter was marked by significant beats on both revenue and profitability, but the results did not prevent a notable drop in the company’s share price. Management attributed the quarter’s strong financials to operational improvements, including earlier identification of high-risk conditions and expanded adoption of clinical pathways, especially in chronic heart failure management. CEO Tim O’Rourke emphasized that these changes are structural rather than short-term fixes, n
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
